Media coverage about Dermira (NASDAQ:DERM) has trended somewhat positive recently, Accern Sentiment Analysis reports. The research group identifies positive and negative press coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Dermira earned a daily sentiment score of 0.12 on Accern’s scale. Accern also assigned headlines about the biopharmaceutical company an impact score of 45.6107790116987 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
These are some of the news headlines that may have impacted Accern’s scoring:
- FY2018 EPS Estimates for Dermira Inc Increased by Leerink Swann (DERM) (americanbankingnews.com)
- Leerink Swann Weighs in on Dermira Inc’s Q1 2018 Earnings (DERM) (americanbankingnews.com)
- Dermira (DERM) PT Raised to $48.00 at Leerink Swann (americanbankingnews.com)
- Dermira (DERM) Given “Buy” Rating at Cantor Fitzgerald (americanbankingnews.com)
Dermira (NASDAQ:DERM) opened at $28.21 on Friday. The company has a quick ratio of 4.68, a current ratio of 4.68 and a debt-to-equity ratio of 1.40. The stock has a market cap of $1,175.62, a PE ratio of -4.53 and a beta of 0.80. Dermira has a twelve month low of $21.35 and a twelve month high of $38.75.
Dermira (NASDAQ:DERM) last announced its quarterly earnings results on Monday, November 6th. The biopharmaceutical company reported ($1.21) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.12) by ($0.09). Dermira had a negative net margin of 992.18% and a negative return on equity of 41.22%. analysts forecast that Dermira will post -7.36 earnings per share for the current fiscal year.
Several analysts have recently commented on the stock. Leerink Swann restated an “outperform” rating and issued a $41.00 target price (down previously from $47.00) on shares of Dermira in a research note on Tuesday, November 7th. Guggenheim assumed coverage on shares of Dermira in a research note on Tuesday, December 5th. They issued a “buy” rating for the company. Mizuho reduced their target price on shares of Dermira from $43.00 to $39.00 and set a “buy” rating for the company in a research note on Tuesday, December 12th. Needham & Company LLC restated a “buy” rating and issued a $43.00 target price (down previously from $46.00) on shares of Dermira in a research note on Tuesday, November 7th. Finally, BidaskClub cut shares of Dermira from a “buy” rating to a “hold” rating in a research note on Tuesday, January 9th. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and six have issued a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus target price of $42.17.
In other news, CEO Thomas G. Wiggans sold 5,000 shares of the stock in a transaction dated Thursday, November 2nd. The shares were sold at an average price of $27.52, for a total value of $137,600.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Eugene A. Bauer sold 3,000 shares of the stock in a transaction dated Monday, December 18th. The shares were sold at an average price of $27.34, for a total transaction of $82,020.00. The disclosure for this sale can be found here. Insiders sold a total of 36,258 shares of company stock valued at $985,873 in the last quarter. Insiders own 13.30% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This news story was originally published by TrueBlueTribune and is owned by of TrueBlueTribune. If you are viewing this news story on another website, it was illegally stolen and republished in violation of United States & international trademark and copyright law. The legal version of this news story can be viewed at https://www.truebluetribune.com/2018/01/21/dermira-derm-receives-media-impact-rating-of-0-12.html.
Dermira, Inc is a biopharmaceutical company. The Company is focused on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis, psoriasis and acne. Its portfolio includes three late-stage product candidates: Cimzia (certolizumab pegol), glycopyrronium tosylate and olumacostat glasaretil.
Receive News & Ratings for Dermira Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira and related companies with MarketBeat.com's FREE daily email newsletter.